Mean Arterial Pressure and Neonatal Outcomes in Pregnancies Complicated by Mild Chronic Hypertension
Matthew D Moore,Hui-Chien Kuo,Rachel G Sinkey,Kim Boggess,Lorraine Dugoff,Baha Sibai,Kirsten Lawrence,Brenna L Hughes,Joseph Bell,Kjersti Aagaard,Rodney K Edwards,Kelly S Gibson,David M Haas,Lauren Plante,Torri D Metz,Brian Casey,Sean Esplin,Sherri Longo,Matthew K Hoffman,George R Saade,Kara K Hoppe,Janelle Foroutan,Methodius Tuuli,Michelle Y Owens,Hyagriv N Simhan,Heather A Frey,Todd Rosen,Anna Palatnik,Susan Baker,Phyllis August,Uma M Reddy,Wendy Kinzler,Emily J Su,Iris Krishna,Nguyet A Nguyen,Mary E Norton,Daniel Skupski,Yasser Y El-Sayed,Dotun Ogunyemi,Ronald Librizzi,Leonardo Pereira,Everett F Magann,Mounira Habli,Shauna Williams,Giancarlo Mari,Gabriella Pridjian,David S McKenna,Marc Parrish,Eugene Chang,Sarah Osmundson,Joanne N Quiñones,Justin Leach,Ayodeji Sanusi,Zorina S Galis,Lorie Harper,Namasivayam Ambalavanan,Jeff M Szychowski,Alan T N Tita
DOI: https://doi.org/10.1097/AOG.0000000000005611
2024-07-01
Abstract:Objective: To estimate the association between mean arterial pressure during pregnancy and neonatal outcomes in participants with chronic hypertension using data from the CHAP (Chronic Hypertension and Pregnancy) trial. Methods: A secondary analysis of the CHAP trial, an open-label, multicenter randomized trial of antihypertensive treatment in pregnancy, was conducted. The CHAP trial enrolled participants with mild chronic hypertension (blood pressure [BP] 140-159/90-104 mm Hg) and singleton pregnancies less than 23 weeks of gestation, randomizing them to active treatment (maintained on antihypertensive therapy with a goal BP below 140/90 mm Hg) or standard treatment (control; antihypertensives withheld unless BP reached 160 mm Hg systolic BP or higher or 105 mm Hg diastolic BP or higher). We used logistic regression to measure the strength of association between mean arterial pressure (average and highest across study visits) and to select neonatal outcomes. Unadjusted and adjusted odds ratios (per 1-unit increase in millimeters of mercury) of the primary neonatal composite outcome (bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, or intraventricular hemorrhage grade 3 or 4) and individual secondary outcomes (neonatal intensive care unit admission [NICU], low birth weight [LBW] below 2,500 g, and small for gestational age [SGA]) were calculated. Results: A total of 2,284 participants were included: 1,155 active and 1,129 control. Adjusted models controlling for randomization group demonstrated that increasing average mean arterial pressure per millimeter of mercury was associated with an increase in each neonatal outcome examined except NEC, specifically neonatal composite (adjusted odds ratio [aOR] 1.12, 95% CI, 1.09-1.16), NICU admission (aOR 1.07, 95% CI, 1.06-1.08), LBW (aOR 1.12, 95% CI, 1.11-1.14), SGA below the fifth percentile (aOR 1.03, 95% CI, 1.01-1.06), and SGA below the 10th percentile (aOR 1.02, 95% CI, 1.01-1.04). Models using the highest mean arterial pressure as opposed to average mean arterial pressure also demonstrated consistent associations. Conclusion: Increasing mean arterial pressure was positively associated with most adverse neonatal outcomes except NEC. Given that the relationship between mean arterial pressure and adverse pregnancy outcomes may not be consistent at all mean arterial pressure levels, future work should attempt to further elucidate whether there is an absolute threshold or relative change in mean arterial pressure at which fetal benefits are optimized along with maternal benefits. Clinical trial registration: ClinicalTrials.gov , NCT02299414.